

EXPLORE

SCINTIX

BIOLOGY-GUIDED RADIOTHERAPY



reflexion

LET CANCER DO THE DRIVING

With SCINTIX™ therapy, for the first time ever, the cancer itself controls treatment delivery for patients with tumors in the lung and bone.



FIRST EVER DUAL-TREATMENT MODALITY PLATFORM

A BREAKOUT ROLE FOR RADIOPHARMACEUTICALS.


SCINTIX biology-guided radiotherapy elevates the performance of injected radiopharmaceuticals to transform tumors into real-time biological beacons. The RefleXion® X1 uses these signals in real time, during treatment, to determine where to deliver radiation. Initially compatible with fludeoxyglucose F18 (FDG) for tumors in the lung or bone, RefleXion seeks to enable SCINTIX therapy for other novel disease-specific radiopharmaceuticals as they become commercially available.

MOTION. MANAGED.

SCINTIX therapy solves the conundrum of targeting and motion management - two of the longest standing barriers preventing radiotherapy for metastatic disease. By using emissions to deliver live targeting data continuously during treatment, this approach reduces the need for motion management techniques such as gating or implanted fiducials and may result in lower toxicity to healthy tissue.

METASTATIC DISEASE. GAME ON.

Finally, a breakthrough technology that brings the cost effectiveness and efficacy of radiotherapy to patients with any stage of cancer. SCINTIX therapy treats patients with tumors in the lung or bone using tumor emissions created during delivery to control radiation therapy. With SCINTIX therapy, clinicians can deliver a conformal dose with potentially smaller margins to spare healthy tissue and preserve dose for additional tumors.



POWERED BY THE REFLEXION X1.


The X1 with SCINTIX therapy is the only hybrid platform offering biologic technology for tumors in motion, and anatomic capabilities via its onboard 16-slice, fan-beam kVCT. SCINTIX therapy, in combination with our state-of-the-art SBRT, SRS, and IMRT, can treat indicated solid tumors of any stage throughout the body.

A NEW RADIOTHERAPY SERVICE LINE.

The X1 treats incremental patients creating a new radiotherapy service line and generating incremental income. With a similar workflow to conventional radiotherapy, preferred treatment planning tools can easily integrate with the X1 platform. And the X1 fits into existing standard-sized LINAC vaults with minimum shielding requirements to reduce the implementation timeline and startup costs. Whether handling your most complex cases or your everyday workload, the RefleXion X1 forms the backbone of any radiotherapy practice.

COME AT CANCER FROM EVERY ANGLE.

Cancer treatment isn't a one-size-fits-all situation. For many patients, clinical evidence suggests the best treatment plan is a combination of multiple therapies. RefleXion can work together with chemotherapy, immunotherapy, and targeted drugs to potentially improve patient outcomes.



reflexion

reflexion.com
25841 Industrial Blvd, Suite 275
Hayward, CA 94545

©2023 RefleXion Medical, Inc. All rights reserved. RefleXion, SCINTIX, their stylized logos, and the RefleXion “X” are trademarks of RefleXion Medical, Inc.

735-00004 Rev D